Abilita Bio was founded in June 2014 and is a biotechnology company focused on enabling discovery and development of drugs targeting membrane proteins, including G Protein Coupled Receptors (GPCRs) and ion channels. We have established collaborations, and seek to expand collaborative research agreements with global pharmaceutical and biotechnology companies. We are currently incubating in JLabs San Diego (a life science innovation center operated by Janssen Research & Development).
Location: United States, California, San Diego
Employees: 1-10
Total raised: $7.5M
Founded date: 2014
Investors 1
| Date | Name | Website |
| 19.02.2022 | Biobrit | biobrit.co... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.02.2023 | - | $7.5M | - |
Mentions in press and media 3
| Date | Title | Description |
| 21.02.2023 | Abilita Bio Secures $7.5M in Financing | Abilita Bio, a San Diego, CA-based leader in discovering and developing membrane protein-targeted therapeutics, raised $7.5M in equity financing. Two Bear Capital made the investment. Mike Goguen, Managing Partner at Two Bear Capital, has j... |
| 21.02.2023 | Abilita Bio receives $7.5M in Funding by Two Bear Capital to accelerate their preclinical programs, grow their team, and expand operations | - |
| - | Abilita Bio | “Abilita Bio – ABILITA BIO IS FOCUSED ON DEVELOPING TECHNOLOGIES TO ENABLE DISCOVERY AND DEVELOPMENT OF DRUGS TARGETING MEMEBRANE PROTEINS, INCLUDING GPCRS, ION CHANNEL AND TRANSPORTERS” |